Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide + aminolevulinic acid
- Development stage
- Unknown
- Lead developer
- Xiangya Hospital, Central South University
- Modality
- Small Molecules
- Administration
- Percutaneous
01
Overview
Triamcinolone acetonide + 5-ALA is a combination drug intervention being investigated for the treatment of refractory skin diseases. It combines triamcinolone acetonide, a synthetic fluorinated corticosteroid that acts as an agonist at intracellular glucocorticoid receptors to suppress inflammation and immune responses, with 5-aminolevulinic acid (5-ALA), a prodrug and porphyrin precursor used in photodynamic therapy. 5-ALA is metabolized to protoporphyrin IX (PpIX) in target tissues, which acts as a photosensitizer. The combination is delivered via a novel piezoelectric-driven microneedle device assisted by ultrasound, which aims to provide more even drug distribution and improved effectiveness compared to traditional injections. This approach is being developed by Xiangya Hospital of Central South University.
- Other names
- triamcinolone acetonide + 5-ALAtriamcinolone acetonide + 5-aminolevulinic acid
02
Targets
GR (Glucocorticoid receptor)PpIX-O2 (Protoporphyrin IX and molecular oxygen)ALAS1 (Delta-aminolevulinate synthase)
Beyond the preview
Go deeper on triamcinolone acetonide + aminolevulinic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide + aminolevulinic acid.